Get the Stockscreener App
147.08
2.52%
-3.80
After Hours:
147.09
0.010
+0.01%
Novartis Ag Adr stock is traded at $147.08, with a volume of 1.87M.
It is down -2.52% in the last 24 hours and down -1.39% over the past month.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
See More
Previous Close:
$150.88
Open:
$149.9
24h Volume:
1.87M
Relative Volume:
1.19
Market Cap:
$280.64B
Revenue:
$54.66B
Net Income/Loss:
$13.58B
P/E Ratio:
20.96
EPS:
7.0171
Net Cash Flow:
$16.05B
1W Performance:
-4.44%
1M Performance:
-1.39%
6M Performance:
+8.73%
1Y Performance:
+26.84%
1-Day Range:
$146.92
$150.08
1-Week Range:
$146.92
$154.22
52-Week Range:
$112.34
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Name
Novartis Ag Adr
Sector
Industry
Phone
-
Address
-
Compare NVS vs LLY, JNJ, ABBV, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
147.08 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,098.57 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.39 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
216.49 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
113.87 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Upgrade | Argus | Hold → Buy |
| Jan-27-26 | Initiated | Citigroup | Buy |
| Jan-06-26 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-12-25 | Downgrade | Goldman | Neutral → Sell |
| Aug-08-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-13-25 | Downgrade | UBS | Buy → Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Underweight |
| Feb-04-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Dec-04-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Sep-11-24 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-05-24 | Downgrade | Goldman | Buy → Neutral |
| Sep-03-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-24 | Downgrade | Deutsche Bank | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-23-24 | Initiated | BMO Capital Markets | Market Perform |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-25-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-26-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-27-23 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-26-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-05-22 | Upgrade | Stifel | Hold → Buy |
| Sep-15-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| May-09-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-10-22 | Resumed | Citigroup | Buy |
| Dec-14-21 | Downgrade | Redburn | Buy → Neutral |
| Dec-06-21 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Sep-20-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-22-21 | Initiated | Bernstein | Mkt Perform |
| Mar-10-21 | Downgrade | Argus | Buy → Hold |
| Feb-01-21 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Sep-10-20 | Upgrade | UBS | Neutral → Buy |
| Sep-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-15-20 | Upgrade | Citigroup | Neutral → Buy |
| Mar-10-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-25-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-10-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Underperform → Buy |
| May-29-18 | Downgrade | HSBC Securities | Buy → Hold |
| May-25-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jan-25-18 | Reiterated | Leerink Partners | Outperform |
| Dec-06-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-17 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jul-05-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Mar-09-17 | Initiated | Liberum | Buy |
View All
Novartis Ag Adr Stock (NVS) Latest News
Why Novartis lets Cosentyx step beyond psoriasis in everyday care - AD HOC NEWS
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Income Statement – BCBA:NVS.CI - TradingView
Preferred dividends of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVS.CI - TradingView
Novartis AG Stock (CH0012005267): Analyst Targets and SMI Role Keep Shares in Focus - AD HOC NEWS
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study - TradingView
Novartis AG Stock (CH0012005267): In focus on a quiet Sunday session - AD HOC NEWS
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) - GlobeNewswire Inc.
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study - Sahm
Novartis AG stock (CH0012005267): Pluvicto data keep focus on Swiss blue-chip pharma - AD HOC NEWS
Novartis AG (ADR) stock (CH0012005267): steady trading ahead of next catalysts - AD HOC NEWS
Novartis AG stock (CH0012005267): shares little changed as investors digest Swiss pharma group’s s - AD HOC NEWS
Novartis AG stock (CH0012005267): focus on Sandoz spin-off and pipeline momentum - AD HOC NEWS
Novartis AG stock (CH0012005267): eyeing Sandoz spin-off and new drug approvals - AD HOC NEWS
Novartis AG stock (CH0012005267): new MS drug filing and Q1 momentum attract attention - AD HOC NEWS
Novartis AG stock (CH0012005267): Q1 update, Sandoz deconsolidation and pharma focus draw investor a - AD HOC NEWS
Novartis AG stock (CH0012005267): oncology focus, new drug readout and solid 2025 guidance in view - AD HOC NEWS
Novartis stock (CH0012005267): FDA progress and market focus - AD HOC NEWS
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG stock (CH0012005267): dividend profile and pipeline focus move into the spotlight - AD HOC NEWS
Novartis AG stock (CH0012005267): US expansion push with new Texas radioligand site - AD HOC NEWS
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis AG stock (CH0012005267): Recent 1.93% gain on SIX Swiss Exchange - AD HOC NEWS
Novartis AG stock (CH0012005267): NewEdge Wealth boosts stake amid mixed analyst views - AD HOC NEWS
NVSNovartis AG ADR Stock Price and Quote - Finviz
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities - ChartMill
Trump's Drug Pricing Deals Could Lead To $529 Billion Savings For The Economy Over The Decade: Report - Sahm
Sandoz, Novartis Must Face Generics Claims From GM, Others - Law360
Novartis Ag Adr Stock (NVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):